Aneta Stefanidis

Suggest Changes
Learn More
OBJECTIVE:Current anti-obesity monotherapies have proven only marginally effective and are often accompanied by adverse side effects. The cannabinoid 1 (CB1) receptor antagonist rimonabant, while(More)